# OnCo record brainchild-bio (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/brainchild-bio/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "brainchild-bio" ;
  schema:name "BrainChild Bio"@en ;
  schema:description "BrainChild Bio develops CAR-T cell therapies for brain tumours, starting with children. Its lead treatment, for diffuse intrinsic pontine glioma, a brainstem tumour of childhood, entered a phase 2 trial in 2026 intended to support an application for approval."@en ;
  schema:url <https://onco.cc/companies/brainchild-bio/>, <https://www.brainchildbio.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.brainchildbio.com/>, <https://www.biospace.com/press-releases/brainchild-bio-closes-116-million-series-a-financing>, <https://clinicaltrials.gov/study/NCT07680439> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/dipg-dmg/>, <https://onco.cc/cancers/glioblastoma/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/glioma-car-t/> ;
  onco:targets <https://onco.cc/targets/b7h3/> ;
  onco:trials <https://onco.cc/trials/nct07680439/> .